Goldman Sachs Group Inc. decreased its stake in Cambrex Corporation (NYSE:CBM) by 33.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 106,483 shares of the biotechnology company’s stock after selling 53,322 shares during the period. Goldman Sachs Group Inc. owned 0.33% of Cambrex Corporation worth $5,862,000 as of its most recent SEC filing.
Several other hedge funds have also recently bought and sold shares of CBM. Flinton Capital Management LLC raised its stake in Cambrex Corporation by 3.8% in the first quarter. Flinton Capital Management LLC now owns 1,870 shares of the biotechnology company’s stock valued at $103,000 after buying an additional 68 shares during the last quarter. YorkBridge Wealth Partners LLC raised its stake in Cambrex Corporation by 20.2% in the first quarter. YorkBridge Wealth Partners LLC now owns 1,874 shares of the biotechnology company’s stock valued at $106,000 after buying an additional 315 shares during the last quarter. Meeder Asset Management Inc. purchased a new stake in Cambrex Corporation during the first quarter valued at $109,000. Dubuque Bank & Trust Co. purchased a new stake in Cambrex Corporation during the first quarter valued at $144,000. Finally, Ameritas Investment Partners Inc. purchased a new stake in Cambrex Corporation during the first quarter valued at $151,000. 98.28% of the stock is owned by institutional investors.
Shares of Cambrex Corporation (NYSE:CBM) opened at 58.90 on Monday. The firm has a market cap of $1.92 billion, a price-to-earnings ratio of 22.42 and a beta of 2.28. Cambrex Corporation has a one year low of $38.30 and a one year high of $62.95. The company has a 50 day moving average of $58.20 and a 200-day moving average of $55.13.
Cambrex Corporation (NYSE:CBM) last issued its quarterly earnings data on Thursday, May 4th. The biotechnology company reported $0.68 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.51 by $0.17. The business had revenue of $105.01 million during the quarter, compared to the consensus estimate of $99.05 million. Cambrex Corporation had a net margin of 17.36% and a return on equity of 24.92%. The firm’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.50 EPS. On average, analysts expect that Cambrex Corporation will post $3.02 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This article was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://sportsperspectives.com/2017/07/24/goldman-sachs-group-inc-has-5-86-million-stake-in-cambrex-corporation-cbm.html.
Several analysts have recently weighed in on the stock. Zacks Investment Research lowered shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, July 4th. ValuEngine lowered shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Finally, BidaskClub raised shares of Cambrex Corporation from a “sell” rating to a “hold” rating in a report on Saturday, June 10th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $64.00.
In related news, CEO Steven M. Klosk sold 12,000 shares of the stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $54.19, for a total value of $650,280.00. Following the completion of the transaction, the chief executive officer now owns 95,328 shares of the company’s stock, valued at approximately $5,165,824.32. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Leon J. Hendrix, Jr. sold 20,656 shares of the stock in a transaction that occurred on Tuesday, June 6th. The shares were sold at an average price of $55.95, for a total transaction of $1,155,703.20. Following the completion of the transaction, the director now directly owns 74,662 shares of the company’s stock, valued at approximately $4,177,338.90. The disclosure for this sale can be found here. In the last three months, insiders sold 70,656 shares of company stock valued at $4,026,143. 2.48% of the stock is owned by insiders.
About Cambrex Corporation
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Corporation (NYSE:CBM).
Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.